Evidence map›Paper›PMID 42182461›Full record

ArticlebioRxiv : the preprint server for biology2026

Joshua J Whiteley, Talia Greenstein, Mariana Pereira Moraes, Maral Budak, Danielle M Weiner, Ayan Abdi, Joel D Fleegle, Felipe Gomez, Laura E Via, Clifton E Barry and 4 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Joshua J WhiteleyDepartment of Biomedical Engineering, Tufts University School of Engineering; Medford, MA, United States.ORCID 0009-0009-3358-0391
Talia GreensteinTufts University School of Graduate Biomedical Sciences; Boston, MA, United States.
Mariana Pereira MoraesDepartment of Molecular Biology and Microbiology, Tufts University School of Medicine; Boston, MA, United States.
Maral BudakDepartment of Microbiology and Immunology, University of Michigan Medical School; Ann Arbor, MI, United States.
Danielle M WeinerTuberculosis Research Section, Laboratory of Clinical Infectious Diseases, NIAID, NIH; Bethesda, MD, United States.
Ayan AbdiTuberculosis Imaging Program, Division of Intramural Research, NIAID, NIH; Bethesda, MD, United States.
Joel D FleegleTuberculosis Imaging Program, Division of Intramural Research, NIAID, NIH; Bethesda, MD, United States.
Felipe GomezTuberculosis Imaging Program, Division of Intramural Research, NIAID, NIH; Bethesda, MD, United States.
Laura E ViaTuberculosis Research Section, Laboratory of Clinical Infectious Diseases, NIAID, NIH; Bethesda, MD, United States.
Clifton E BarryTuberculosis Research Section, Laboratory of Clinical Infectious Diseases, NIAID, NIH; Bethesda, MD, United States.
Jansy SarathyCenter for Discovery and Innovation, Hackensack Meridian Health; Nutley, NJ, United States.
Denise KirschnerDepartment of Microbiology and Immunology, University of Michigan Medical School; Ann Arbor, MI, United States.
Veronique DartoisCenter for Discovery and Innovation, Hackensack Meridian Health; Nutley, NJ, United States.
Bree B AldridgeDepartment of Biomedical Engineering, Tufts University School of Engineering; Medford, MA, United States.ORCID 0000-0003-2236-1424

Funding

Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) ConsortiumUM1AI179699 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Kelly E. Dooley, ERIC L NUERMBERGER · 2024 to 2026
$22.2M
Lesion-centric optimization of multidrug therapies for tuberculosisR01AI150684 · NIAID · TUFTS UNIVERSITY BOSTON · PI ALDRIDGE, BREE BEARDSLEY, KIRSCHNER, DENISE E · 2020 to 2024
$4.2M
Bill & Melinda Gates Foundation INV-027276NIAID NIH HHS R01 AI150684NIAID NIH HHS UM1 AI179699
6 · The paper itself

Abstract

Tuberculosis lesions are structurally and physiologically heterogeneous, creating microenvironments that restrict antibiotic penetration and alter bacterial susceptibility. This heterogeneity remains a major impediment to shortening tuberculosis treatment, as it is difficult to predict which regimens will sterilize bacteria in these hard-to-treat lesion niches. Many

Identifiers

PMID42182461
PMCPMC13192695

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.